Study title:
Milano GM et al High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.Cancer 2006 Apr 15;106(8):1838-45. Erratum in: Cancer 2006 Sep 15;107(6):1421Milano GM et al High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.Cancer 2006 Apr 15;106(8):1838-45. Erratum in: Cancer 2006 Sep 15;107(6):1421
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report, Please see report, Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: CYCLOPHOSPHAMIDE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
Y
|